TY - JOUR T1 - SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting JF - medRxiv DO - 10.1101/2022.01.13.22268861 SP - 2022.01.13.22268861 AU - Kirsten E. Lyke AU - Robert L. Atmar AU - Clara Dominguez Islas AU - Christine M. Posavad AU - Daniel Szydlo AU - Rahul PaulChourdhury AU - Meagan E. Deming AU - Amanda Eaton AU - Lisa A. Jackson AU - Angela R. Branche AU - Hana M. El Sahly AU - Christina A. Rostad AU - Judith M. Martin AU - Christine Johnston AU - Richard E. Rupp AU - Mark J. Mulligan AU - Rebecca C. Brady AU - Robert W. Frenck, Jr. AU - Martín Bäcker AU - Angelica C. Kottkamp AU - Tara M. Babu AU - Kumaravel Rajakumar AU - Srilatha Edupuganti AU - David Dobrzynski AU - Rhea N. Coler AU - Janet I. Archer AU - Sonja Crandon AU - Jillian A. Zemanek AU - Elizabeth R. Brown AU - Kathleen M. Neuzil AU - David S. Stephens AU - Diane J. Post AU - Seema U. Nayak AU - Paul C. Roberts AU - John H. Beigel AU - David Montefiori AU - the DMID 21-0012 Study Group Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/14/2022.01.13.22268861.abstract N2 - As part of an ongoing study assessing homologous and heterologous booster vaccines, following primary EUA series, we assessed neutralization of D614G and Omicron variants prior to and 28 days after boost. Subset analysis was done in six combinations (N = 10/group): four homologous primary-booster combinations included mRNA-1273 two-dose priming followed by boosting with 100-μg or 50-μg mRNA-1273, Ad26.COV2.S single-dose priming followed by Ad26.COV2.S booster and BNT162b2 two-dose priming followed by BNT162b2 boosting; and two heterologous primary-booster combinations: BNT162b2 followed by Ad26.COV2.S and Ad26.COV2.S followed by BNT162b2. Neutralizing antibody (Nab) titers to D614G on the day of boost (baseline) were detected in 85-100% of participants, with geometric mean titers (GMT) of 71-343 in participants who received an mRNA vaccine series versus GMTs of 35-41 in participants primed with Ad26.OV2.S. Baseline NAb titers to Omicron were detected in 50-90% of participants who received an mRNA vaccine series (GMT range 12.8-24.5) versus 20-25% among participants primed with Ad26.COV2.S. The booster dose increased the neutralizing GMT in most combinations to above 1000 for D614G and above 250 for Omicron by Day 29. Homologous prime-boost Ad26.COV2.S had the lowest NAb on Day 29 (D614G GMT 128 and Omicron GMT 45). Results were similar between age groups. Most homologous and heterologous boost combinations examined will increase humoral immunity to the Omicron variant.Competing Interest StatementRLA, CPDI, CMP, DS, RP, MED, AE, HME, RER, MB, ACK, TMB, DD, RNC, JLA, SC, JAZ, SUN, ERB, DJP, and SUN report no competing interests. KEL receives grant awards from Pfizer Inc COVID-19 vaccine research. LAJ receives grant funding from NIH and CDC for vaccine-related assessments, including those of COVID-19 vaccines. ARB has grant funding from Pfizer, Janssen, Merck and Cyanvac for non-Covid-related work and serves as a consultant for GSK and Janssen. CAR has received funds to conduct clinical research from the National Institutes of Health, CDC, BioFire Inc, Genentech, GSK, Janssen, MedImmune, Merck, Micron, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology, which has been licensed to Meissa Vaccines, Inc. JMM has served as a consultant for Merck, Sharp and Dohme for non-Covid-related work. CJ receives funding from the Bill and Melinda Gates Foundation, NIH and CDC, consults for Gilead and Abbvie, serves on a DSMB for MedPace, and receives royalties from UpToDate. MJM has laboratory research and clinical trials contracts for vaccines or MAB vs SARS-CoV-2 with Lilly, Pfizer (exclusive of the current work), and Sanofi; personal fees for Scientific Advisory Board service from Merck, Meissa Vaccines, Inc. and Pfizer RCB receives funding for vaccine trials from Path Nipah and Pfizer. RWF receives funding to perform clinical trials from Pfizer, Moderna, Astra Zeneca and Emergent Health, and he serves on advisory boards for Johnson & Johnson, Merck, Sanofi Pasteur and Seqirus. SE receives funding to her institution from Sanofi Pasteur for a non-Dovid vaccine study. KMN holds a grant from Pfizer, without salary support, for a COVID-19 vaccine study, and salary support from the National Institutes of Health (NIH) for work on multiple COVID-19 vaccine trials DSS is supported by grant awards from NIH/NIAID PCR and JHB report a pending U.S. Patent Application No. 63/025,918 entitled, Coronavirus RNA vaccines and methods of use. DCM receives funding from NIH and Moderna for laboratory studies of COVID-19 vaccine antibody responses. Clinical TrialNCT04889209Funding StatementThe trial was sponsored and primarily funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), under award numbers UM1AI48372, UM1AI148373, UM1AI148450, UM1AI148452, UM1AI148573, UM1AI148574, UM1AI148575, UM1AI148576, UM1AI148684, UM1 AI148689 and with support from the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00050 and NIH Vaccine Research Center. We would like to acknowledge Moderna, Inc., Johnson & Johnson/Janssen, and Pfizer/BioNTech Pharmaceuticals for their collaboration, scientific input, and sharing of documents needed to implement this trial. All products were acquired through the government procurement process. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra has provided ethical and regulatory oversight as part of a multi-center IRB. Local IRBs maintained oversight for each of the ten study sites but had a reliance agreement with Advarra.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -